Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.62 |
| ▸ | CCR2 | P41597 | 4/20 | 0.62 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5413188 | 0.99 | ROCK2 (0.61) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL5413248 | 0.90 | CA12 (0.53) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL13106874 | 0.85 | KDM4E (0.51) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL14514348 | 0.84 | ROCK2 (0.57) | ROCK2ROCK1CCR2DRD4SIGMAR1 | |
| SCHEMBL13106873 | 0.79 | FAAH (0.56) | ROCK2ROCK1ACHEKDM4E | |
| SCHEMBL13106898 | 0.79 | NPC1 (0.45) | ROCK2ROCK1GRIN2BITK | |
| SCHEMBL13106905 | 0.78 | NPC1 (0.53) | ROCK2ACHE | |
| SCHEMBL13106880 | 0.78 | HRH3 (0.44) | ROCK2DRD4SIGMAR1TMEM97HRH3 | |
| SCHEMBL5408219 | 0.78 | ROCK2 (0.59) | ROCK2ROCK1CCR2GRIN2BACHE | |
| SCHEMBL3313890 | 0.77 | ROCK2 (0.64) | ROCK2ROCK1CCR2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885CCR2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.